NASDAQ: KRMDKoru Medical Systems Inc Stock
$2.14+0.01 (+0.47%)
Updated Apr 23, 2024
KRMD Price
$2.14
Fair Value Price
-$2.15
Market Cap
$97.82M
52 Week Low
$1.98
52 Week High
$4.48
P/E
-7.13x
P/B
4.81x
P/S
3.93x
PEG
N/A
Dividend Yield
N/A
Revenue
$28.52M
Earnings
-$13.74M
Gross Margin
58.6%
Operating Margin
-34.27%
Profit Margin
-48.2%
Debt to Equity
0.4
Operating Cash Flow
-$5M
Beta
0.83
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
KRMD Overview
KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. It offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company also provides education and training materials to clinicians, patients, and patient advocates. It sells its products through direct sales and medical device distributors, as well as online. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York.
Zen Score
–
Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KRMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KRMD ($2.14) is overvalued by 199.37% relative to our estimate of its Fair Value price of -$2.15 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KRMD ($2.14) is not significantly undervalued (199.37%) relative to our estimate of its Fair Value price of -$2.15 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KRMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KRMD due diligence checks available for Premium users.
Be the first to know about important KRMD news, forecast changes, insider trades & much more!
KRMD News
Valuation
KRMD fair value
Fair Value of KRMD stock based on Discounted Cash Flow (DCF)
Price
$2.14
Fair Value
-$2.15
Undervalued by
199.37%
KRMD ($2.14) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KRMD ($2.14) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KRMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KRMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.13x
Industry
48.7x
Market
41.92x
KRMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.81x
Industry
3.54x
KRMD is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KRMD's financial health
Profit margin
Revenue
$7.2M
Net Income
-$7.5M
Profit Margin
-103.9%
KRMD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
KRMD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$28.5M
Liabilities
$8.1M
Debt to equity
0.4
KRMD's short-term assets ($20.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KRMD's short-term assets ($20.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KRMD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KRMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$1.1M
Investing
-$208.4k
Financing
-$178.4k
KRMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KRMD vs Medical Stocks
Koru Medical Systems Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.